Identifying Barriers to and optiMizing In-hosPitaL usE of Evidenced-based Medical thErapies for patieNTs With Cardio-Renal-Metabolic Disease
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 200
- 试验地点
- 2
- 主要终点
- Proportion of patients prescribed SGLT2i (sodium glucose co-transporter-2 inhibitors)
研究概览
简要总结
This study will be a prospective randomized implementation trial for patients hospitalized with heart failure, chronic kidney disease, and/or type 2 diabetes mellitus within Duke University Medical Center. The primary hypothesis is that a virtual quality improvement-based consult intervention will improve the rate of in-hospital evidence-based cardio-renal-metabolic medication use, particularly SGLT2 inhibitor therapy. Approximately 200 patients meeting eligibility criteria will be included in the study. Patients will be assigned into study groups, as defined by randomization of their treating clinician team to receiving the virtual consult versus not.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Health Services Research
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Hospitalized adults age ≥ 18 years with ≥1 of the following diagnoses, as defined by the medical record:
- •HF (any ejection fraction)
- •CKD with estimated GFR ≥ 20 mL/min/1.73m2 *
- •T2DM (by clinical history or hemoglobin A1c)
排除标准
- •End-stage stage renal disease on dialysis or eGFR <20 mL/kg/1.73m
- •Pre-menopausal woman who are either breast-feeding or pregnant
- •History of heart transplant or actively listed for heart transplant
- •Implanted left ventricular assist device or implant anticipated within 3 months.
- •Enrolled in or planning to enroll in hospice care.
- •Active cancer (except localized prostate, breast, or non-melanoma skin cancers)
结局指标
主要结局
Proportion of patients prescribed SGLT2i (sodium glucose co-transporter-2 inhibitors)
时间窗: 30 days post-discharge (approximately 6 weeks)
次要结局
未报告次要终点